Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Arrowhead Pharmaceuticals Inc Common Stock (ARWR).
- Disclosed ownership: 11%.
- Date of event: 30 Jun 2025.
VANGUARD GROUP INC - 30 Jun 2025 SCHEDULE 13G/A Report for Arrowhead Pharmaceuticals Inc Common Stock (ARWR)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- ARWR
- Shares outstanding
- 138,123,416 shares
- Disclosed Ownership
- 15,525,072 shares
- Ownership
- 11%
- Form type
- SCHEDULE 13G/A
- Filing time
- 29 Jul 2025, 11:20:42 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 26 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 11% ownership in Arrowhead Pharmaceuticals Inc Common Stock (ARWR) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 29 Jul 2025, 11:20.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 11% | 15,525,072 | 0 | 142,962 | Ashley Grim | Head of Global Fund Administration |